The “2022 Retinal Pharmaceuticals Market Report” now covers more development-stage categories, therapies, and companies and features updated disease prevalence data, which now includes all NPDR. The report examines anti-VEGF treatment patterns and ophthalmologists’ adoption plans for Beovu and biosimilars.
Sales forecasts have been updated through 2027; an outlook for sustained drug delivery and IVT injection shares by indication in the United States is now included.
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.